Gjc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.90 Cr
- Revenue Growth -86.54%
- Profit Growth -3751.55%
- Ebitda -197.44%
- Net Worth -6.05%
- Total Assets 45.34%
About Gjc Pharmaceuticals
Gjc Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 February 2017 (Seven years and 11 months 18 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.90 Cr.
Gajanan Jalindar, Priyanka Gajanan, and Prashant Jalindar serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290PN2017PTC169064
-
Company No.
169064
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Feb 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Gjc Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gajanan Jalindar
|
Managing Director | 22-Feb-2017 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Priyanka Gajanan
|
Director | 22-Feb-2017 | Current |
|
Prashant Jalindar
|
Director | 22-Feb-2017 | Current |
Financial Performance of Gjc Pharmaceuticals.
Gjc Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 86.54% decrease. The company also saw a substantial fall in profitability, with a 3751.55% decrease in profit. The company's net worth dipped by a decrease of 6.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gjc Pharmaceuticals?
In 2020, Gjc Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.90 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 3.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Mar 2022 | Others | ₹5.50 M | Open |
| 21 Dec 2020 | Others | ₹3.35 Cr | Open |
How Many Employees Work at Gjc Pharmaceuticals?
Unlock and access historical data on people associated with Gjc Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gjc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gjc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.